Całościowa ocena przewlekłej obturacyjnej choroby płuc według raportu GOLD 2011

• Authors: Iwona Grzelewska-Rzymowska , Paweł Górski

Title variants

EN

Combined assessment of chronic obstructive pulmonary disease according to GOLD report 2011

• Languages of publication: PL

Abstracts

PL

Autorzy omawiają nowe podejście do przewlekłej obturacyjnej choroby płuc, przedstawione w raporcie GOLD 2011. Przewlekła obturacyjna choroba płuc jest ogólnoświatowym problemem zdrowotnym. Badanie BOLD ujawniło, że rozpowszechnienie choroby jest różne w poszczególnych krajach i będzie czwartą przyczyną zgonów w 2030 roku. Główną przyczyną przewlekłej obturacyjnej choroby płuc jest nałóg palenia tytoniu. Raport GOLD 2011 zaleca, aby postawienie diagnozy rozważyć, jeśli pacjent prezentuje takie objawy, jak: duszność, kaszel i odkrztuszanie wydzieliny z ekspozycją na czynniki ryzyka oraz z obecnością obturacji potwierdzonej wartością FEV1/ FVC < 0,70. Wskaźnik FEV1 okazał się niedostatecznym deskryptorem wpływu przewlekłej obturacyjnej choroby płuc na pacjenta. Jest to choroba złożona i różnorodna, zbadanie jej wpływu na zdrowie pacjenta wymaga walidowanych testów, takich jak BODE, ADO, DOSE. Raport GOLD 2011 zaleca stosowanie dwóch walidowanych testów: mMRC i CAT. Wskaźniki wentylacyjne są sklasyfikowane jako GOLD 1 i 2 (zaburzenia łagodne i umiarkowane) oraz GOLD 3 i 4 (zaburzenia ciężkie i bardzo ciężkie). Zaostrzenia przewlekłej obturacyjnej choroby płuc są ustalane na podstawie wywiadu lub wartości FEV1. Ostatecznie pacjentów można zakwalifikować do kategorii A, B, C lub D. Leczenie farmakologiczne powinno być ustalane po dokonaniu zindywidualizowanej oceny.

EN

In this paper authors present a new approach to chronic obstructive pulmonary disease patients according to GOLD report 2011. Chronic obstructive pulmonary disease is a global health problem. The BOLD study proved that prevalence of it vary across countries and this disease will be the fourth leading cause of death in 2030. The main cause of chronic obstructive pulmonary disease is tobacco smoking. GOLD report 2011 recommends that a clinical diagnosis of a disease should be considered in patients presenting such symptoms as dyspnoea, cough, sputum expectoration as well as relevant exposure to risk factors with the presence of persistent airflow limitation confirmed by post-bronchodilat or FEV1/FVC < 0.70. The FEV1 is an inadequate descriptor of the impact of chronic obstructive pulmonary disease on patients. It is a complex and heterogeneous disease and that is why the validated tests are proposed – i.e. BODE index, ADO and DOSE – to examine the impact of chronic obstructive pulmonary disease on patients. GOLD report 2011 recommends the use of two validated tests: mMRC questionnaire and COPD Assessment Test (CAT). Spirometric values are classified as GOLD 1 and 2 (mild and moderate) and GOLD 3 and 4 (severe and very severe). Exacerbations of chronic obstructive pulmonary disease are based on the individual patient’s history or FEV1. Finally, the chronic obstructive pulmonary disease patients are classified to category A, B, C or D. Pharmacological treatment should be based on an individualized assessment.

Keywords

EN

B; C; C and D of COPD; D POChP; GOLD report 2011; categories A; całościowa; chronic obstructive pulmonary disease (COPD); cigarette smoking; combined assessment of COPD; kategorie A; ocena POChP; palenie tytoniu; przewlekła obturacyjna choroba płuc (POChP); raport GOLD 2011

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Pediatria i Medycyna Rodzinna
• Year: 2013
• Volume: 9
• Issue: 2
• Pages: 135–143

Contributors

author

Iwona Grzelewska-Rzymowska

• Klinika Pneumonologii i Alergologii I Katedry Chorób Wewnętrznych, Uniwersytet Medyczny w Łodzi. Kierownik Kliniki: prof. dr hab. n. med. Paweł Górski

author

Paweł Górski

• Klinika Pneumonologii i Alergologii I Katedry Chorób Wewnętrznych, Uniwersytet Medyczny w Łodzi. Kierownik Kliniki: prof. dr hab. n. med. Paweł Górski

References

• 1. Mathers C.D., Loncar D.: Projections of global mortality and burden of disease from 2002 to 2030. PloS Med. 2006; 3: e442.
• 2. Rabe K.F., Hurd S., Anzueto A. i wsp.; Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532–555.
• 3. GOLD. Global Strategy for Diagnosis, Management, and Prevention of COPD. Updated 2011. Adres: www. goldcopd.org/Guidelines/guidelines-resources.html (cytowany 9 sierpnia 2012 r.).
• 4. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Updated 2013. Adres: www.goldcopd.org/guidelines-global-strategy-for-diagnosis- management.html (cytowany w lutym 2013 r.).
• 5. Agusti A., Calverley P.M., Celli B. i wsp.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122–136.
• 6. Curkendall S.M., Lanes S., de Luise C. i wsp.: Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 21: 803–813.
• 7. Soriano J.B., Alfageme I., Almagro P. i wsp.: Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest 2013;143: 694–702.
• 8. Fabbri L., Luppi F., Beghe B., Rabe K.: Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 204–212.
• 9. Celli B.R., Cote C.G., Marin J.M. i wsp.: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–1012.
• 10. Puhan M.A., Garcia-Aymerich J., Frey M. i wsp.: Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704–711.
• 11. Jones R.C., Donaldson G.C., Chavannes N.H. i wsp.: Derivation and validation of a composite index of severity in Chronic Obstructive Pulmonary Disease The DOSE Index. Am. J. Respir. Crit. Care Med. 2009; 180: 1189–1195.
• 12. Bestall J.C., Paul E.A., Garrod R. i wsp.: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586.
• 13. Jones P.W., Harding G., Wiklund I. i wsp.: Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012; 142: 134–140.
• 14. Qaseem A., Wilt T.J., Weinberger S.E. i wsp.: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179–191.
• 15. Anthonisen N.R., Connett J.E., Kiley J.P. i wsp.: Effects of smoking intervention and use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 271: 149–155.
• 16. de Marco R., Accordini S., Marcon A. i wsp.: Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011; 183: 891–897.
• 17. Mannino D.M., Homa D.M., Akinbami L.J. i wsp.: Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51: 1–16.
• 18. Soriano J.B., Maier W.C., Egger P. i wsp.: Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789–794.
• 19. Kohansal R., Martinez-Camblor P., Agusti A. i wsp.: The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3–10.
• 20. Fletcher C., Peto R.: The Natural history of chronic airflow obstruction. Br. Med. J. 1997; 1: 1645–1648.
• 21. Anthonisen N.R., Skeans M.A., Wise R.A. i wsp.; Lung Health Study Research Group: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.
• 22. Zagdańska R., Grzelewka-Rzymowska I.: Ocena spadku wartości wskaźnika FEV1 po 3 latach obserwacji u chorych na ciężką astmę i POChP. Pneumonol. Alergol. Pol. 2004; 72: 307.
• 23. Casanova C., de Torres J.P., Aguirre-Jaime A. i wsp.: The progression of chronic obstructive pulmonary disease is heterogenous. The experience of the BODE cohort. Am. J. Respir. Crit. Care Med. 2011; 184: 1015–1021.
• 24. Anthonisen N.R., Connett J.E., Murray R.P.; Lung Health Study Research Group: Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675–679.
• 25. Menezes A.M., Perez-Padilla R., Jardim J.R. i wsp.; PLATINO Team: Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875–1881.
• 26. Zieliński J., Bednarek M.: Early detection of COPD in a high-risk population using spirometric screening. Chest 2001; 119: 731–736.
• 27. Zieliński J., Bednarek M., Górecka D. i wsp.: Increasing COPD awareness. Eur. Respir. J. 2006; 27: 833–852.
• 28. Buist A.S., McBurnie M.A., Vollmer W.M. i wsp.; BOLD Collaborative Research Group: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.
• 29. Niżankowska-Mogilnicka E., Mejza F., Buist S. i wsp.: Częstość występowania POChP i rozpowszechnienie palenia tytoniu w Małopolsce – wyniki badania BOLD w Polsce. Pol. Arch. Med. Wewn. 2007; 117: 402–409.
• 30. Grzelewska-Rzymowska I., Kroczyńska-Bednarek J., Kaczanowska E.: Testy czynności płuc i nadreaktywość oskrzeli w astmie. Pediatr. Med. Rodz. 2009; 5: 145–151, 168.
• 31. O’Brien C., Guest P.J., Hill S.L., Stockley R.A.: Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635–642.
• 32. van Schayck C.P., Loozen J.M., Wagena E. i wsp.: Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 2002; 324: 1370.
• 33. Seemungal T.A., Donaldson G.C., Paul E.A. i wsp.: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.
• 34. Calverley P.M., Anderson J.A., Celli B. i wsp.; TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.
• 35. Decramer M., Celli B., Kesten S. i wsp.: Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374: 1171–1178.
• 36. Hurst J.R., Vestbo J., Anzueto A. i wsp.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.
• 37. Wedzicha J.A.: GOLD and ABCD – a good start, but now for the evidence? Lancet Respir. Med. 2012; Special Preview: 2–3.
• 38. Han M.K., Muellerova H., Curran-Everett D. i wsp.: GOLD 2011 disease severity classification in the COPDGene study: a prospective cohort study. Lancet Respir. Med. 2012; Special Preview: 15–22.
• 39. Grzelewska-Rzymowska I., Patora-Mikołajczyk J., Górski P.: Combined assessment of COPD according to GOLD report 2011. Pol. Arch. Intern. Med. 2013. W druku.
• 40. Spencer S., Calverley P.M., Burge P.S., Jones P.W.: Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J. 2004; 23: 698–702.
• 41. Boyd C.M., Darer J., Boult C. i wsp.: Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases implications for pay for performance. JAMA 2005; 294: 716–724.
• 42. Scanlon P.D., Connett J.E., Waller L.A. i wsp.; Lung Health Study Research Group: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161: 381–390.
• 43. Mannino D.M., Thorn D., Swensen A., Holguin F.: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008; 32: 962–969.
• 44. Incalzi R.A., Fuso L., De Rosa M. i wsp.: Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794–2800.
• 45. Celli B., Jones P., Vestbo J. i wsp.: The multidimensional BOD: association with mortality in the TORCH trial. Eur. Respir. J. 2008; 32 supl. 52: 42s.
• 46. Szafranski W., Cukier A., Ramirez A. i wsp.: Efficacy and safety of budesonide/formoterol in the management of COPD. Eur. Respir. J. 2003; 21: 74–87.
• 47. Suissa S., Dell’Aniello S., Ernst P.: Long-term natural history of COPD: severe exacerbations and mortality. Thorax 2012; 67: 957–963.
• 48. Vogelmeier C., Hederer B., Glaab T. i wsp.: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. Med. 2011; 364: 1093–1103.
• 49. Singh D., Brooks J., Hagan G. i wsp.: Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592–598.
• 50. Rabe K.F.: Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2010; 4: 543–555.
• 51. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

• Document Type: article